Tokushima University / Educator and Researcher Directory --- Tanaka, Hironori

Personal Web Page

https://orcid.org/0000-0003-4712-0192 (ORCID)

Field of Study

Subject of Study

Book / Paper

Book:

1.	Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌におけるレンバチニブの治療成績., Arcmedium, Jan. 2019.

Academic Paper (Judged Full Paper):

1.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Aasahiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice., JGH Open, Vol.8, No.10, e70033, 2024. (Summary) We aimed to evaluate the efficacy and safety of durvalumab plus tremelimumab (Dur + Tre) combination therapy in patients with unresectable hepatocellular carcinoma (uHCC) in clinical practice. We retrospectively evaluated 37 patients with uHCC from our institutions between April 2023 and January 2024. Patients were divided into first- and later-line groups for analysis of antitumor efficacy, adverse events (AEs), and transition rate to second-line treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST). The disease control rate (DCR) for the first-line group was 80.9%, which was significantly higher than that for the later-line group (50%). The incidence of immune-related AEs (irAEs) was 24.3%, with grade 3 or higher irAEs including increased transaminase (8.1%), diarrhea (8.1%), and adrenal insufficiency (2.7%). The rates of drug withdrawal and discontinuation owing to AEs were 23.8% and 19%, respectively, in the first-line treatment and 31.2% and 12.5%, respectively, in the later-line treatment, with no significant difference. Analysis of changes in liver reserve using the albumin-bilirubin (ALBI) score showed no obvious loss of liver reserve for up to 12 weeks. The transition rate from first- to second-line therapy after progressive disease (PD) was as high as 94.7%. The efficacy and safety of Dur + Tre in clinical practice were comparable to those reported in a recent phase III trial. The first-line Dur + Tre therapy had a higher DCR than that of the later lines, and the transition rate to second-line therapy was considerably high, suggesting that Dur + Tre therapy would be more beneficial in first-line treatment. (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.70033 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39371045 ● Search Scopus @ Elsevier (PMID): 39371045 ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.70033 (DOI: 10.1002/jgh3.70033, PubMed: 39371045)
2.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Shota Fujimoto, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study., Scientific Reports, Vol.14, No.1, 22446, 2024. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-024-73429-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39341964 ● Search Scopus @ Elsevier (PMID): 39341964 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-73429-1 (DOI: 10.1038/s41598-024-73429-1, PubMed: 39341964)
3.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study., Journal of Gastroenterology and Hepatology, Vol.39, No.6, 1107-1114, 2024. (Summary) Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged 50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged 50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16530 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514 ● Search Scopus @ Elsevier (PMID): 38419514 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530 (DOI: 10.1111/jgh.16530, PubMed: 38419514)
4.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease., Diabetes & Metabolic Syndrome, Vol.18, No.5, 103036, 2024. (Summary) Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes. Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with >2 health checkups over >2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage. Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (p < 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (p < 0.01 and p < 0.001, respectively). Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission. (Keyword) Humans / Male / Female / Body Mass Index / Middle Aged / Non-alcoholic Fatty Liver Disease / Waist Circumference / Adult / Remission Induction / Follow-Up Studies / Prognosis / Metabolic Diseases (Link to Publication Site) ● Publication site (DOI): 10.1016/j.dsx.2024.103036 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38754333 ● Search Scopus @ Elsevier (PMID): 38754333 ● Search Scopus @ Elsevier (DOI): 10.1016/j.dsx.2024.103036 (DOI: 10.1016/j.dsx.2024.103036, PubMed: 38754333)
5.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, shota Fujimoto, Tomoyuki Kawaguchi, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study., European Journal of Clinical Investigation, Vol.Online ahead of print., e14221, 2024. (Summary) The influence of alcohol intake on metabolic dysfunction-associated fatty liver disease (MAFLD) development and remission remains unclear; thus, we aimed to investigate their longitudinal associations. This observational cohort study included 6349 patients who underwent more than two health check-ups over >2 years between April 2013 and March 2021. Generalized estimation equations were used to analyse the longitudinal associations between changes in alcohol intake and MAFLD according to repeated measures at baseline and the most recent stage. The MAFLD development and remission rates were 20.4 and 5.1 and 9.1 and 4.7% in men and women, respectively. Although alcohol consumption was not a significant factor for MAFLD development, consuming 0.1-69.9 g/week (odds ratio [OR]: 0.672, 95% confidence interval [CI]: 0.469-0.964, p < .05) and ≥280 g/week were significant factors for MAFLD development in males (OR: 1.796, 95% CI: 1.009-3.196, p < .05) and females (OR: 16.74, 95% CI: 3.877-72.24, p < .001). Regardless of quantity and frequency, alcohol consumption was not a significant factor for MAFLD remission. Several noninvasive liver fibrosis scores were significantly associated with alcohol intake quantity and frequency in males with MAFLD development and remission (p < .05). The nonalcoholic fatty liver disease fibrosis score differed significantly between males with and without reduced alcohol intake (p < .05) who showed MAFLD remission. Although the influence of alcohol intake on MAFLD development and remission differed, alcohol consumption was not beneficial for MAFLD remission in either sex. Alcohol intake reduction or cessation is recommended to prevent liver fibrosis, even in those who achieve MAFLD remission. (Link to Publication Site) ● Publication site (DOI): 10.1111/eci.14221 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38634705 ● Search Scopus @ Elsevier (PMID): 38634705 ● Search Scopus @ Elsevier (DOI): 10.1111/eci.14221 (DOI: 10.1111/eci.14221, PubMed: 38634705)
6.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study., Journal of Gastroenterology and Hepatology, Vol.39, No.4, 754-761, 2024. (Summary) The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged 50 years is important for gallstone prevention. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16483 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880 ● Search Scopus @ Elsevier (PMID): 38212880 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483 (DOI: 10.1111/jgh.16483, PubMed: 38212880)
7.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Shigekazu Sugino, Jun Suzuki, Masaki Fujishima, Eri Okumura, Hideo Takekoshi, Osamu Uehara, Shintaro Sugita, Yoshihiro Abiko, Tetsu Tomonari, Hironori Tanaka, Hidekatsu Takeda and Tetsuji Takayama : Acanthopanax senticosus ameliorates steatohepatitis through HNF4 alpha pathway activation in mice., Scientific Reports, Vol.14, No.1, 110, 2024. (Summary) Non-alcoholic fatty liver disease is a common liver disease worldwide, and is associated with dysregulation of lipid metabolism, leading to inflammation and fibrosis. Acanthopanax senticosus Harms (ASH) is widely used in traditional medicine as an adaptogen food. We examined the effect of ASH on steatohepatitis using a high-fat diet mouse model. Mice were fed a choline-deficient, L-amino acid-defined, high-fat diet with ASH extract (ASHE). After 6 weeks, liver RNA transcriptome sequencing (RNA-Seq) was performed, followed by Ingenuity Pathway Analysis (IPA). Our findings revealed that mice fed a high-fat diet with 5% ASHE exhibited significantly reduced liver steatosis. These mice also demonstrated alleviated inflammation and reduced fibrosis in the liver. IPA of RNA-Seq indicated that hepatocyte nuclear factor 4 alpha (HNF4 alpha), a transcription factor, was the activated upstream regulator (P-value 0.00155, z score = 2.413) in the liver of ASHE-fed mice. Adenosine triphosphate binding cassette transporter 8 and carboxylesterase 2, downstream targets of HNF4 alpha pathway, were upregulated. Finally, ASHE-treated HepG2 cells exposed to palmitate exhibited significantly decreased lipid droplet contents. Our study provides that ASHE can activate HNF4 alpha pathway and promote fat secretion from hepatocytes, thereby serving as a prophylactic treatment for steatohepatitis in mice. (Keyword) Animals / Mice / Hepatocyte Nuclear Factor 4 / Eleutherococcus / Liver / Non-alcoholic Fatty Liver Disease / Inflammation / Disease Models, Animal / Fibrosis / Mice, Inbred C57BL / Diet, High-Fat (Tokushima University Institutional Repository) ● Metadata: 119444 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-50625-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38167633 ● Search Scopus @ Elsevier (PMID): 38167633 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-50625-z (Tokushima University Institutional Repository: 119444, DOI: 10.1038/s41598-023-50625-z, PubMed: 38167633)
8.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Asahiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Tsutomu Masaki and Tetsuji Takayama : Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma., Cancers, Vol.15, No.21, 5221, 2023. (Summary) <jats:p>This retrospective multicenter study analyzed 244 patients with unresectable hepatocellular carcinoma treated with lenvatinib (LEN) and atezolizumab + bevacizumab (Atezo + Bev) to examine the characteristics, treatment courses, and prognoses. The cases of patients who could achieve HCC downstaging from Barcelona Clinic Liver Cancer (BCLC) stage B or C to A or zero indicated the need for conversion therapy. The patients' prognoses with and without conversion therapy were compared. Of the 244 patients, 12 (4.9%) underwent conversion therapy, six out of 131 (4.6%) were treated with LEN, and six out of 113 (5.3%) were treated with Atezo + Bev. Eleven patients (91.7%) with a modified albumin bilirubin (mALBI) grade 1 or 2a and BCLC-B stage showed significantly higher rates of transition during conversion therapy (p < 0.05). The patients undergoing conversion therapy had a significantly longer median overall survival rate than those receiving chemotherapy alone (1208 [1064–NA] vs. 569 [466–704] days, p < 0.01). A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064–NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.</jats:p> (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers15215221 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1360580235903920000 ● Summary page in Scopus @ Elsevier: 2-s2.0-85176601973 (DOI: 10.3390/cancers15215221, CiNii: 1360580235903920000, Elsevier: Scopus)
9.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study., Clinical Nutrition, Vol.42, No.5, 810-816, 2023. (Summary) The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676-1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753-1.439, p = 0.808); the OR for women who drank 140-279.9 g/week was 2.135 (95% CI, 1.158-3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD (p < 0.005). Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD. (Tokushima University Institutional Repository) ● Metadata: 118599 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clnu.2023.03.020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37043935 ● Search Scopus @ Elsevier (PMID): 37043935 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clnu.2023.03.020 (Tokushima University Institutional Repository: 118599, DOI: 10.1016/j.clnu.2023.03.020, PubMed: 37043935)
10.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments., Clinical Journal of Gastroenterology, Vol.16, No.3, 438-443, 2023. (Summary) The efficacy of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN-TACE) has been reported, but its effect on unresectable hepatocellular carcinoma (HCC) refractory to LEN therapy has not been demonstrated. We report a case of HCC refractory to multiple molecular-targeted agents (MTA) treatments, including LEN, that was successfully treated with LEN-TACE. A 59-year-old man was referred to our department with multiple HCCs and a background of hepatitis B virus infection. TACE was the initial treatment. However, he was determined to be TACE-refractory, and multitargeted therapy was initiated. LEN was started at 12 mg/day but resulted in progressive disease (PD) after 13 months of the administration. The response to second-line sorafenib was PD after 2 months. Third-line therapy with atezolizumab + bevacizumab was stopped after one course because of an immune-related adverse event (i.e., dermatitis). The response to fourth-line regorafenib was PD at 2 months, and the response to fifth-line cabozantinib was PD after 6 months. The efficacy of LEN-TACE was recently reported; therefore, we decided to attempt LEN-TACE therapy as a salvage line. After obtaining the patient's consent to repeat LEN and TACE, treatment was initiated. The tumor markers levels markedly reduced after LEN-TACE therapy. After three additional TACE treatments with continued LEN administration, the tumor marker levels normalized, and complete response was determined based on RECIST guidelines. LEN-TACE therapy may effectively treat unresectable advanced HCC in the LEN-rechallenge setting and may be a treatment option as a last-line therapeutic option. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-023-01777-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36856957 ● Search Scopus @ Elsevier (PMID): 36856957 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-023-01777-y (DOI: 10.1007/s12328-023-01777-y, PubMed: 36856957)
11.	Tetsu Tomonari, Joji Tani, Chikara Ogawa, Akihiro Deguchi, Tomonori Senoh, Akio Moriya, Hiroshi Shibata, Hiroshi Fukuno, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Yutaka Kawano, Akihiro Morishita, Koichi Takaguchi, Hiroshi Miyamoto, Yasushi Sato, Tsutomu Masaki and Tetsuji Takayama : Multicenter retrospective study of Initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma., Hepatology Research, Vol.53, No.2, 172-178, 2023. (Summary) Cabozantinib (CAB), a multiple kinase inhibitor, has been approved for use in patients with previously treated unresectable hepatocellular carcinoma (uHCC). However, real-world clinical data are lacking, particularly clinical data regarding dose modifications of CAB. We analyzed the clinical outcomes of CAB in uHCC and compared treatment outcomes between the full- and reduced-dose groups. This multicenter, observational study included patients with uHCC who were treated with CAB from March 2021 to April 2022. Patient characteristics, efficacy, and safety were compared between the full- and reduced-dose groups. Twenty-six patients from eight institutes were analyzed. Cabozantinib was administered as a third-line or later treatment in 25 (96.2%) patients and postimmunotherapy in 21 (80.5%) patients. There were 15 patients in the full-dose group (60 mg CAB) and 11 in the reduced-dose group (40 or 20 mg CAB). The objective response rate (ORR) and disease control rate (DCR) were not significantly different between the two groups. The ORR was 6.7% for the full-dose group and 9.1% for the reduced-dose group, and the DCR was 53.4% and 81.8%, respectively. Progression-free survival analysis showed no significant differences between the two groups. The incidence of decreased appetite, fatigue, and diarrhea, and the rate of discontinuation and dose reduction, was significantly higher in the full-dose group. Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13845 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36214071 ● Search Scopus @ Elsevier (PMID): 36214071 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13845 (DOI: 10.1111/hepr.13845, PubMed: 36214071)
12.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Akihiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki and Tetsuji Takayama : Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve., Cancer Medicine, Vol.12, No.3, 2646-2657, 2023. (Summary) We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC). In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group. In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a. (Tokushima University Institutional Repository) ● Metadata: 117987 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.5145 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35964253 ● Search Scopus @ Elsevier (PMID): 35964253 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.5145 (Tokushima University Institutional Repository: 117987, DOI: 10.1002/cam4.5145, PubMed: 35964253)
13.	Yasushi Sato, Yasuyuki Okada, Yasuteru Fujino, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Hironori Tanaka, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Masahiro Sogabe and Tetsuji Takayama : Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 154-159, 2023. (Summary) In Japan, cancer genome profiling (CGP) for cancer patients without standard treatment has been covered by public insurance since June 2019. This study analyzed data of 122 patients with gastrointestinal tumors who underwent CGP to clarify cancer genome medicine's current status and possible problems at the Tokushima University Hospital. The major types of cancer included pancreatic (n=30), colorectal (n=25), biliary tract (n=15), gastric (n=11), and hepatocellular carcinoma (n=8). CGP tests included F1CDx in 70 patients (57%), F1LCDx in 36 (30%), TSO500 in 14 (11%), and NCC Oncopanel in 2 (2%). Actionable gene alterations were identified in 72 patients (59%), but only 5 patients (4%) were treated for pancreatic (n=1), colorectal (n=3), and small bowel cancers (n=1). The main reasons for not receiving genotype-matched therapy included the lack of appropriate drugs or clinical trials that matched the actionable gene alterations (n=40) and the inability to participate in clinical trials (n=10). There is still not a sufficient number of patients receiving genotype-matched treatment for gastrointestinal cancers. To promote cancer genome medicine in regional areas, attempts to improve access to genotype-matched therapies are required, as well as to promote the development of new molecular-targeted drugs and clinical trials for these drugs. J. Med. Invest. 70 : 154-159, February, 2023. (Keyword) Humans / Gastrointestinal Neoplasms / Neoplasms / Colorectal Neoplasms / Genomics / Hospitals / Japan (Tokushima University Institutional Repository) ● Metadata: 118346 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.154 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164713 ● Search Scopus @ Elsevier (PMID): 37164713 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.154 (Tokushima University Institutional Repository: 118346, DOI: 10.2152/jmi.70.154, PubMed: 37164713)
14.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study., Nutrients, Vol.14, No.22, 4760, 2022. (Summary) The influence of changes in alcohol consumption on erosive esophagitis (EE) development in both sexes is unclear. This observational study investigated sex differences in the influence of alcohol consumption on EE development, and included 2582 patients without EE at baseline from 13,448 patients who underwent >2 health check-ups over >1 year. The rates of non-drinkers who started drinking, and drinkers who abstained from drinking, who increased, and who decreased their weekly alcohol consumption were 7.2%, 9.7%, 14.7%, and 24.1% and 7.3%, 17.8%, 12.8%, and 39.0% in men and women, respectively. In the final cohort, 211/1405 (15.0%) men and 79/1177 (6.7%) women newly developed EE. The odds ratio (OR) for drinking in EE development was 1.252 (95% confidence interval (CI), 0.907-1.726) among men and 1.078 (95% CI, 0.666-1.747) among women. Among men aged <50 years, the OR for drinking ≥70 g/week in EE development was 2.825 (95% CI, 1.427-5.592), whereas among women, the OR for drinking ≥140 g/week in EE development was 3.248 (95% CI, 1.646-6.410). Among participants aged <50 years, the OR for daily drinking in EE development was 2.692 (95% CI, 1.298-5.586) among men and 4.030 (95% CI, 1.404-11.57) among women. The influence of alcohol consumption on EE development differed between the sexes. We recommend no alcohol consumption for individuals aged <50 years to avoid EE development. Daily drinkers should be assessed for EE development. (Keyword) Humans / Male / Female / Longitudinal Studies / Alcohol Drinking / Esophagitis / Sexual Behavior / Cohort Studies / Peptic Ulcer (Tokushima University Institutional Repository) ● Metadata: 118071 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu14224760 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36432447 ● Search Scopus @ Elsevier (PMID): 36432447 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14224760 (Tokushima University Institutional Repository: 118071, DOI: 10.3390/nu14224760, PubMed: 36432447)
15.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Miwako Kagawa, Hiroyuki Ueda, Tomoyuki Kawaguchi, Akira Fukuya, Kaizoh Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females., Scientific Reports, Vol.12, No.1, 16048, 2022. (Summary) The clinical difference between nonalcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) between the two sexes is unclear. This study aimed to determine the influences of alcohol consumption and qualitative abdominal fat between male and female patients with NAFLD and MAFLD. This cross-sectional study examined 11,766 participants who underwent health check-ups comparing lifestyle habits, biochemical features, and noninvasive liver fibrosis scores, between non-MAFLD and MAFLD groups. Furthermore, differences in alcohol consumption and qualitative abdominal fat were examined between male and female patients with NAFLD and MAFLD. The prevalence of metabolic dysregulation, ratio of visceral fat area to subcutaneous fat area, and noninvasive liver fibrosis scores were significantly higher in male patients with MAFLD than in those with NAFLD (p < 0.05), but these were not significantly different in female patients. Among male patients with an alcohol consumption of > 70 g/week, several noninvasive liver fibrosis scores were significantly higher in the MAFLD group than in the NAFLD group (all p < 0.05). The influences of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD were different between sexes. The development of liver fibrosis should be considered in male patients with MAFLD who exceed mild drinking. (Keyword) Alcohol Drinking / Cross-Sectional Studies / Female / Humans / Intra-Abdominal Fat / Liver Cirrhosis / Male / Non-alcoholic Fatty Liver Disease (Tokushima University Institutional Repository) ● Metadata: 117853 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-20124-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36163355 ● Search Scopus @ Elsevier (PMID): 36163355 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-20124-8 (Tokushima University Institutional Repository: 117853, DOI: 10.1038/s41598-022-20124-8, PubMed: 36163355)
16.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma., JGH Open, Vol.5, No.11, 1275-1283, 2021. (Tokushima University Institutional Repository) ● Metadata: 116741 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12663 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.12663 (Tokushima University Institutional Repository: 116741, DOI: 10.1002/jgh3.12663)
17.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi and Tetsuji Takayama : MiR-125b-5p is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma., Cancers, Vol.13, No.19, 4917, 2021. (Summary) The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression-findings similar to those for PLC/PRF5-R2-which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients. (Tokushima University Institutional Repository) ● Metadata: 116647 (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers13194917 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34638401 ● Search Scopus @ Elsevier (PMID): 34638401 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers13194917 (Tokushima University Institutional Repository: 116647, DOI: 10.3390/cancers13194917, PubMed: 34638401)
18.	Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama : Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis., Hepatology Research, Vol.51, No.4, 472-481, 2021. (Summary) The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first-line treatment for unresectable hepatocellular carcinoma (u-HCC) remains debatable. Using propensity score matching, this study compares the outcomes of SOR and LEN in the molecular-targeted agent (MTA) sequential treatment of u-HCC patients. This retrospective, multicenter, observational study recruited 137 u-HCC patients who underwent primary treatment with LEN (n = 52) or SOR (n = 85) between June 2017 and June 2020 after regorafenib was approved as the secondary treatment for u-HCC. Propensity score matching was used to reduce confounding, resulting in the selection of 104 patients (n = 52 for the SOR and LEN cohorts). The median overall survival was 21.8 months for LEN and 20.4 months for SOR. LEN exhibited significantly greater therapeutic efficacy as compared to SOR (objective response rate: 3.8% [SOR] vs. 42.3% [LEN], P <0.01; progression-free survival: 10 months [LEN] vs. 5.1 months [SOR], P <0.01). No significant intergroup differences were noted in the rate of transition to secondary MTA treatments (SOR: 58.7%; LEN: 48.4%), adverse events (SOR: 86%; LEN: 95%), and maintenance of the Child-Pugh (CP) score during treatment. Compared to non-MTA treatments, secondary MTA treatment achieved a greater improvement in survival ( 4.3 months vs. 2.8 months, P=0.0047). Multivariate analysis demonstrated that the CP score (P <0.01) and alpha-fetoprotein level (P <0.01) were independent prognostic factors. Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13597 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33238074 ● Search Scopus @ Elsevier (PMID): 33238074 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13597 (DOI: 10.1111/hepr.13597, PubMed: 33238074)
19.	Hironori Tanaka, Yoshihito Saijyo, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi, Shusuke Yagi, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, Masataka Sata and Tetsuji Takayama : An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration, Internal Medicine, Vol.60, No.12, 1839-1845, 2021. (Summary) A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved. (Tokushima University Institutional Repository) ● Metadata: 116336 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.5914-20 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456037 ● Search Scopus @ Elsevier (PMID): 33456037 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.5914-20 (Tokushima University Institutional Repository: 116336, DOI: 10.2169/internalmedicine.5914-20, PubMed: 33456037)
20.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports., Medicine, Vol.99, No.42, e22782, 2020. (Summary) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (Keyword) Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins (Tokushima University Institutional Repository) ● Metadata: 116240 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000022782 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748 ● Search Scopus @ Elsevier (PMID): 33080748 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782 (Tokushima University Institutional Repository: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748)
21.	Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Masanori Takehara, Kaizoh Kagemoto, Jun Okazaki, Yoshifumi Kida, Akihiro Hirao, Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Nakasono and Tetsuji Takayama : Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome., PLoS ONE, Vol.15, No.8, e0238388, 2020. (Summary) The prevalence of nonalcoholic fatty liver disease (NAFLD) in the non-obese population has increased and NAFLD is not always recognized in individuals with metabolic syndrome (MS). The risk of cirrhosis is higher in patients having NAFLD with elevated alanine aminotransferase (ALT) levels than in those having NAFLD with normal ALT levels. To measure the differences in clinical factors associated with NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and to measure differences in metabolites between MS subjects with and without NAFLD having elevation of ALT. Among 7,054 persons undergoing health check-ups, we included 3,025 subjects who met the selection criteria. We measured differences in clinical factors for NAFLD having elevation of ALT among subjects with Non-MS, Pre-MS, and MS, and compared metabolites between subjects with and without NAFLD having elevation of ALT in 32 subjects with MS. The prevalence of NAFLD and NAFLD having elevation of ALT was significantly progressively greater in subjects with Non-MS, Pre-MS, and MS (p <0.001, respectively). In the Non-MS group, there were significant differences between subjects with and without NAFLD having elevation of ALT with respect to body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, hemoglobin A1c, uric acid, aspartate aminotransferase (AST); In the Pre-MS group, there were significant differences in BMI, hypertension, AST, and gamma-glutamyl transpeptidase (GGT); In the MS group, there were significant differences in HDL-C, impaired glucose tolerance, AST, and GGT. There were significant differences in levels of metabolites of nicotinamide, inosine, and acetyl-L-carnitine between MS subjects with and without NAFLD having elevation of ALT (all p <0.05). Although NAFLD having elevation of ALT is important for development of NAFLD, differences in factors associated with NAFLD having elevation of ALT at various stages of MS should be considered. Additionally, several metabolites may play roles in the identification of risk for NAFLD in individuals with MS. (Tokushima University Institutional Repository) ● Metadata: 115614 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0238388 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32866186 ● Search Scopus @ Elsevier (PMID): 32866186 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0238388 (Tokushima University Institutional Repository: 115614, DOI: 10.1371/journal.pone.0238388, PubMed: 32866186)
22.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma, JGH Open, Vol.4, No.6, 1135-1139, 2020. (Summary) Abstract Background and Aim Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN. Methods (Patients) and Results A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3 (Tokushima University Institutional Repository) ● Metadata: 115923 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33319048 ● Summary page in Scopus @ Elsevier: 2-s2.0-85089378719 (Tokushima University Institutional Repository: 115923, DOI: 10.1002/jgh3.12408, PubMed: 33319048, Elsevier: Scopus)
23.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
24.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Yasuteru Fujino, Yasuhiro Mitsui, Akihiro Hirao, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Harumi Kagiwada, Masashi Kitazawa, Kazuhiro Fukui, Ktsuhisa Horimoto and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array., Oncotarget, Vol.11, No.26, 2531-2542, 2020. (Summary) The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group ( < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR. (Tokushima University Institutional Repository) ● Metadata: 116246 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27640 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32655838 ● Search Scopus @ Elsevier (PMID): 32655838 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27640 (Tokushima University Institutional Repository: 116246, DOI: 10.18632/oncotarget.27640, PubMed: 32655838)
25.	Masahiro Sogabe, Toshiya Okahisa, Akira Fukuya, Kaizoh Kagemoto, Yasuyuki Okada, Yuka Adachi, Takeshi Kurihara, Toru Nii, Satoshi Teramae, Hironori Tanaka, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Masahiko Nakasono and Tetsuji Takayama : Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial., BMC Gastroenterology, Vol.20, No.1, 122, 2020. (Summary) Esophagogastroduodenoscopy (EGD) provides an indispensable and unambiguous inspection allowing the discovery upper gastrointestinal lesions. However, many patients are anxious about undergoing EGD. Few studies have investigated the influence on patients' vital signs and tolerance during EGD using subjective and objective assessments. This study was a prospective randomized controlled study that investigated the influence of audio and visual distraction on EGD. We randomly divided 289 subjects who underwent EGD into 4 groups (control group, audio group, visual group, combination group) and examined their vital signs, heart rate variability (HRV), psychological items, and acceptance of distraction. Pulse rate (PR) at post-distraction and post-EGD in the 3 distraction groups were significantly lower than those of control group (p < 0.001 and p < 0.01, respectively). Blood pressure (BP) during and post-EGD was significantly higher than that at pre-EGD in control group (p < 0.05), but no significant elevation of BP was observed during the latter half of EGD and post-EGD in the 3 distraction groups. BP at post-distraction improved significantly compared to pre-distraction in the 3 distraction groups (p < 0.05). There was a significant difference in the low-frequency (LF) power/ high-frequency (HF) power at post-distraction and post-EGD among the 4 groups (p < 0.001 and p < 0.001, respectively). The LF power/HF power at post-distraction and post-EGD in the 3 distraction groups was significantly lower than that in control group (p < 0.05). Several items of profile of mood states (POMS) and the impression of EGD at post-distraction improved significantly compared to those at pre-distraction among the 3 distraction groups (p < 0.05). Visual analog scale (VAS) of willingness for the next use of distraction in the 3 distraction groups was excellent because VAS was more than 70. Distractions effectively improved psychological factors, vital signs and some of HRV at pre and post-EGD. Distractions may suppress BP elevation during the latter half of EGD and lead to stability of HRV on EGD. This prospective trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000029637. Registered on 20 October 2017. (Tokushima University Institutional Repository) ● Metadata: 114760 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-020-01274-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32316918 ● Search Scopus @ Elsevier (PMID): 32316918 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-020-01274-3 (Tokushima University Institutional Repository: 114760, DOI: 10.1186/s12876-020-01274-3, PubMed: 32316918)
26.	Rie Harada, Masako Kimura, Yasushi Sato, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Naoki Muguruma, Hirohiko Shinomiya, Hirohito Honda, Issei Imoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism., BMC Gastroenterology, Vol.18, No.1, 24, 2018. (Summary) It has been reported that some single-nucleotide polymorphisms (SNPs) in lipid regulators such as apolipoproteins and cell surface molecules for hepatitis C virus (HCV) entry into hepatocytes are associated with HCV infection. However, it is unknown how HCV infection is affected by altered lipid metabolism resulting from the SNPs. We investigated the relationship between these SNPs and HCV infection status, and also analyzed the mechanism by which these SNPs mediate HCV infection via lipid metabolism alterations. Serum lipid and apolipoprotein profiles were tested in 158 HCV-positive and 220 HCV-negative subjects. We selected 22 SNPs in five lipid regulator genes which were related to HCV entry into hepatocytes and to lipid metabolism (APOA1, APOB, SR-B1, LDLR, and APOE), and their polymorphisms were analyzed using the PCR-sequence-specific oligonucleotide probe-Luminex method. An APOB N4311S (g.41553a > g) SNP, rs1042034, was significantly associated with HCV positivity; the HCV positivity rate for the minor allele AA genotype was significantly higher than for genotype AG + GG (P = 0.016). Other SNPs except for APOB P2712L SNP rs676210, which is in linkage disequilibrium with rs1042034, showed no significant difference in genotype distribution. The serum level of low density lipoprotein-cholesterol (LDL-C) in the genotype AA group was significantly lower than in the genotype non-AA group (P = 0.032), whereas the triglyceride (TG) level was significantly higher (P = 0.007). An APOB SNP, rs1042034, is closely associated with HCV infection through lipid metabolism alteration. The minor allele AA genotype might contribute to facilitating serum LDL uptake into hepatocytes via LDLR by modifying their affinity and interaction and may have an influence on HCV infection by their entry to the liver through the LDLR. (Tokushima University Institutional Repository) ● Metadata: 111808 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-018-0747-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29382324 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041353404 (Tokushima University Institutional Repository: 111808, DOI: 10.1186/s12876-018-0747-5, PubMed: 29382324, Elsevier: Scopus)

Proceeding of International Conference:

1.	Hironori Tanaka, Tetsu Tomonari, Ryo Shinomiya, Mai Yonezawa, Yutaka Kawano and Tetsuji Takayama : Usefulness of shear wave elastography for evaluation of HCC recurrence after ablation., APASL2024, Kyoto, Mar. 2024.
2.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama : Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax Senticosus, ameliorates steatohepatitis in high-fat fed mice model., AASLD2023, Boston, Nov. 2023.
3.	Yutaka Kawano, Maki Tanaka, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takeshi Mitsuhashi and Tetsuji Takayama : Activation of HNF4α pathway by treatment with botanical plant, Acanthopanax senticosus, ameliorates steatohepatitis in high-fat fed mice model., DDW2023, Chicago, May 2023.
4.	Hironori Tanaka, Tetsu Tomonari, Reika Matsumoto, Kazuyoshi Noda, Tatsuya Taniguchi and Tetsuji Takayama : Usefulness of shear wave elastography for evaluation of hepatocellular carcinoma recurrence after ablation therapy., ACTA 2021(7th conference on Tumor Ablation), Oct. 2021.
5.	Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Hirao Akihiro, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Kagiwada Harumi, Kitazawa Masashi, Fukui Kazuhiko, Horimoto Katsuhisa and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array, ASCO Gastrointestinal Cancers Symposium(ASCO-GI 2020), San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.485 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.485 (DOI: 10.1200/JCO.2020.38.4_suppl.485)
6.	Naoki Muguruma, Fujimoto Daisaku, Yasuteru Fujino, Kashihara Takanori, Kazuyoshi Noda, Fukuya Akira, Takehara Masanori, Hirao Akihiro, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari and Tetsuji Takayama : Linked Color Imaging System in the Endoscopic Detection of Sessile Serrated Adenoma/Polyp, Korea International Digestive Endoscopy Congress 2019, Aug. 2019. (Keyword) Image-enhanced endoscopy / Linked color imaging / Sessile serrated adenoma/polyp
7.	Naoki Igata, J nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Drainage with Normal Saline in Two Directions for Washing of the Clogging Filter During Cell-free and Concentrated Ascites Reinfusion Therapy., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
8.	junji nishioka, T Komatsu, S Kobayashi, Y Ohnishi, M Fukuhara, Hironori Tanaka, Tetsu Tomonari, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Development of Multiple Point Bowel-sound Analysis System (MPBAS) for the Optimization of the Bowel Sound Measurement Position., The 65th Annual Conference of American Society for Artificial Internal Organs (ASAIO), San Francisco, Jun. 2019.
9.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma., digestive disease week2019, San Diego, May 2019.
10.	Tadahiko Nakagawa, Yoshifumi Takaoka, Hironori Tanaka, Kumiko Tanaka, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Masatake Akutagawa, Takahiro Emoto, Yohsuke Kinouchi, Toru Murashima, Satoru Yamaji, Zenji Tanaka, Masahiro Sogabe and Toshiya Okahisa : Roller Pump Circulation System For Preventing Filter Clogging During Cell-free and Concentrated Ascites Reinfusion Therapy (cart)., The 61th Annual Conference of American Society for Artificial Internal Organs(ASAIO), Chicago, Jun. 2015.

Proceeding of Domestic Conference:

1.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : Shear wave elastography(SWE)およびUltrasound-Guided Attenuation Parameter(UGAP)を用いた肝脂肪化，線維化の評価., JDDW2024, Nov. 2024.
2.	Hiroyuki Ueda, Hironori Tanaka, Kenichi Yoneda, 米澤真衣, Tetsu Tomonari, Yutaka Kawano and Tetsuji Takayama : <パネルディスカッション>食道静脈瘤の評価におけるMR Elastographyの有用性., 第31回日本門脈圧亢進症学会総会, Sep. 2024.
3.	takeshi mitsuhashi, Yutaka Kawano, Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, 米澤真衣 and Tetsuji Takayama : フィトケミカル食品エゾウコギを用いたMAFLD/MASH に対する有効性の基礎検討., 第31回日本がん予防学会総会(日本がん予防学会学術大会2024徳島), Sep. 2024.
4.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Yutaka Kawano, 森下朝洋, 正木勉 and Tetsuji Takayama : 切除不能肝細胞癌に対する後治療を見据えたデュルバルマブ+トレメリムマブ併用療法の治療成績., 第30回日本肝がん分子標的治療研究会, Jul. 2024.
5.	Hironori Tanaka, Tetsu Tomonari, Yutaka Kawano and Tetsuji Takayama : 肝細胞癌に対する定位放射線療法の有効性., 第60回肝癌研究会, Jul. 2024.
6.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : <ワークショップ>Shear wave elastographyによる肝細胞癌焼灼術後の肝内異所性再発リスク評価., 第60回日本肝臓学会総会, Jun. 2024.
7.	Hironori Tanaka, 米澤真衣, Tetsu Tomonari, Yutaka Kawano and Tetsuji Takayama : Ultrasound-guided attenuation parameter(UGAP)を用いた肝脂肪化の評価., 日本超音波医学会第97回学術集会, Jun. 2024.
8.	Hironori Tanaka, Tetsu Tomonari, mai yonezawa, Yutaka Kawano and Tetsuji Takayama : <ワークショップ>食道静脈瘤の評価におけるMR Elastographyの有用性., 第110回日本消化器病学会総会, May 2024.
9.	米澤真衣, Hironori Tanaka, Tetsu Tomonari, Yutaka Kawano and Tetsuji Takayama : <シンポジウム>肝脂肪化の評価におけるultrasound-guided attenuation parameter(UGAP)の有用性., 第110回日本消化器病学会総会, May 2024.
10.	Tetsuji Takayama and Hironori Tanaka : <教育講演6>抗がん薬の消化器毒性とその対策, 第1232回日本内科学会講演会, Apr. 2024.
11.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Yutaka Kawano, 森下朝洋, 正木勉 and Tetsuji Takayama : 切除不能肝細胞癌に対するデュルバルマブ+トレメリムマブ併用療法の初期治療成績., 第29回日本肝がん分子標的治療研究会, Jan. 2024.
12.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌局所穿刺療法困難症例に対する定位放射線療法の治療成績., 第45回日本肝臓学会西部会, Dec. 2023.
13.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : MR Elastography によるNAFLDの肝線維化評価., JDDW2023, Nov. 2023.
14.	Yutaka Kawano, 渡邉奈々恵, 西山正彦, 小野薫, Yasushi Sato, 照井健, 日下部俊郎, Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : がん関連疲労に対するエゾウコギ含有食品の実行可能性試験., 第 61 回日本癌治療学会学術集会, Oct. 2023.
15.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌に対する定位放射線療法の治療成績., 第59回日本肝癌研究会, Jul. 2023.
16.	Tetsu Tomonari, Hironori Tanaka, Yutaka Kawano, Yasushi Sato and Tetsuji Takayama : デュルバルマブ+トレメリムマブ併用療法を見据えた肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療戦略., 第28回日本肝がん分子標的治療研究会, Jun. 2023.
17.	Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : 肝細胞癌に対する定位放射線療法の治療成績., 第59回日本肝臓学会総会, Jun. 2023.
18.	Tetsu Tomonari, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Hiroshi Miyamoto and Tetsuji Takayama : 悪性肝腫瘍に対するEmprint Ablation Systemの治療成績., 日本超音波医学会第96回学術集会, May 2023.
19.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 高リスク食道静脈瘤の評価におけるMR Elastographyの有用性., 第109回日本消化器病学会総会, Apr. 2023.
20.	平田圭市郎, Hiroyuki Ueda, takanori miyake, takanori kashihara, Yasuyuki Okada, Hironori Tanaka, hironori wada, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Takashi Kawanaka, Hitoshi Ikushima, Yoshimi Bando, Yasushi Sato and Tetsuji Takayama : 切除不能・再発膵神経内分泌腫瘍(pancreatic neruoendocrine neoplasm:P-NEN)に対する集学的治療による治療成績の向上., 第109回日本消化器病学会総会, Apr. 2023.
21.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano, Tsutomu Masaki and Tetsuji Takayama : アテゾリズマブ+ベバシズマブ，レンバチニブを用いた切除不能肝細胞癌に対する根治的Conversion therapyの治療成績., 第20回日本臨床腫瘍学会学術集会, Mar. 2023.
22.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Tatsuya Taniguchi, 正木勉 and Tetsuji Takayama : 切除不能進行肝癌に対するAblationを用いたCenversion療法の可能性., 第1回日本アブレーション研究会, Feb. 2023.
23.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : Shear wave elastgraphyによる肝細胞癌焼灼術後の再発リスク評価., 第1回日本アブレーション研究会, Feb. 2023.
24.	Tetsu Tomonari, Hironori Tanaka, Tatsuya Taniguchi, Yutaka Kawano and Tetsuji Takayama : 切除不能進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法後のレンバチニブ及び根底的Conversion治療の有効性., 第27回日本肝がん分子標的治療研究会, Jan. 2023.
25.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : Shear wave elastographyによる肝細胞癌焼灼術後の再発リスク評価., JDDW2022(第30回日本消化器関連学会週間), Oct. 2022.
26.	Hironori Wada, Yasuyuki Okada, Tatsuya Taniguchi, Hironori Tanaka, Koichi Okamoto and Tetsuji Takayama : Wntシグナル伝達経路を標的とした大腸癌の化学予防., 第81回日本癌学会学術総会, Oct. 2022.
27.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 正木勉 and Tetsuji Takayama : 肝癌薬物療法における根治的Combination therapyの有効性, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
28.	Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi and Tetsuji Takayama : NAFLD/NASHの線維化評価におけるME Elastographyの有用性., 第58回日本肝臓学会総会, Jun. 2022.
29.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対する根治的Combination therapyの有効性., 第58回日本肝癌研究会, May 2022.
30.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Naoki Muguruma, Kensei Nishida and Tetsuji Takayama : 肝細胞癌においてmiR-125b-5pは上皮間葉転換を引き起こし，ソラフェニブに対して耐性を獲得する, 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
31.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝洋, Yasushi Sato, 正木勉 and Tetsuji Takayama : 後治療を見据えた肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療戦略., 第25回日本肝がん分子標的治療研究会, Jan. 2022.
32.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝洋, 正木勉 and Tetsuji Takayama : 薬物療法既治療例を含む切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療成績., JDDW2021(第29回日本消化器医関連学会週間), Nov. 2021.
33.	Hironori Tanaka, Tetsu Tomonari, kaizo kagemoto, Yasuyuki Okada, hironori wada, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 免疫チェックポイント阻害薬投与中の肝障害., 第59回日本癌治療学会学術集会, Oct. 2021.
34.	Rei Mizobuchi, Hironori Tanaka, Naoya Tani, Kazuyoshi Noda, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Tomomi Matsuura, Masataka Sata and Tetsuji Takayama : 超音波観察を併用することで安全に治療した高度腎機能低下を合併した猪瀬型肝性脳症の1例, 第263回徳島医学会学術集会, Aug. 2021.
35.	Tetsu Tomonari, 谷丈二, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, 森下朝弘, 正木勉 and Tetsuji Takayama : 薬物療法既治療例を含む切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の初期治療成績., 第24回日本肝がん分子標的治療研究会, Aug. 2021.
36.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : Therapeutic strategy of lenvatinib for hepatocelluar carcinoma in intermediate-stage., 第57回日本肝癌研究会, Jul. 2021.
37.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能肝癌に対するアテゾリズマブ+ベバシズマブ併用療法の薬物療法既治療例を含む初期治療成績., 第57回日本肝臓学会総会, Jun. 2021.
38.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi and Tetsuji Takayama : 肝細胞癌焼灼術後の再発リスク評価における超音波エラストグラフィの有用性, 日本超音波医学会第94 回学術集会, May 2021.
39.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 高リスク食道胃静脈瘤の評価におけるMR Elastographyの有用性., 第107回日本消化器病学会総会, Apr. 2021.
40.	Hironori Tanaka and Tetsuji Takayama : 肝細胞癌に対するミリプラチン併用化学放射線療法の検討., 第39回Cytoprotection研究会, Mar. 2021.
41.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 悪性肝腫瘍に対するEmprint Ablation Systemの治療成績-多血肝細胞癌の肝動脈塞栓術併用療法を中心にー, 第56回日本肝癌研究会, Dec. 2020.
42.	折野逸人, Nobuhito Naito, 内藤仁美, 髙橋直希, Hironori Tanaka, Seidai Satou, Hiroshi Kawano, Hisanori Uehara, Hiroshi Nokihara, Tetsuji Takayama and Yasuhiko Nishioka : 肝肺症候群に進展したサルコイドーシスの1例, 第64回日本呼吸器学会中国・四国地方会, Nov. 2020.
43.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対するLenvatinib治療後のSorafenib, Ramucirumabの治療成績., 第22回日本肝がん分子標的治療研究会, Nov. 2020.
44.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌におけるLenvatinibを用いたConversion therapyの治療成績., 第28回消化器関連学会週間(JDDW2020), Nov. 2020.
45.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Yu Saitou, Satoru Imura, Mitsuo Shimada and Tetsuji Takayama : 進行肝癌におけるLenvatinibを用いたConversion Therapyの可能性―肝切除, Microwave ablation, 肝動脈塞栓術による追加治療の検討―., 第21回日本肝がん分子標的治療研究会, Jan. 2020.
46.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 進行肝癌におけるレンバチニブの最適な投与タイミングの検討., JDDW2019(第27回日本消化器関連学会週間), Nov. 2019.
47.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 免疫チェックポイント阻害薬による肝障害―作用機序との関連についてー., JDDW2019(第27回日本消化器関連学会週間), Nov. 2019.
48.	yoshihiko miyamoto, Naoki Muguruma, yasuyuki okada, Hironori Tanaka, Jun Okazaki, Koichi Okamoto, Yasushi Sato and Tetsuji Takayama : EGFR-targeted molecular imaging for detection and treatment evaluation of colorectal tumors in animal model., 第78回日本癌学会学術総会, Sep. 2019.
49.	Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
50.	Jinsei Miyoshi, 村山典聡, Satoshi Teramae, 宮本佳彦, Hironori Tanaka, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Takahiro Tanaka, Kumiko Tanaka, 松村圭一郎, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 直腸NETのmicroRNA網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
51.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 進行肝癌に対するレンバチニブの治療経過における肝予備能の推移., 日本肝がん分子標的治療研究会, Jun. 2019.
52.	山本加奈子, Hironori Tanaka and Tetsuji Takayama : 食道静脈瘤高危険群の拾い上げにおけるMR Elastographyの有用性., 第55回日本肝臓学会総会, May 2019.
53.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 免疫チェックポイント阻害薬による肝胆道障害の検討., 第55回日本肝臓学会総会, May 2019.
54.	Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka and Tetsuji Takayama : 切除不能進行肝癌に対する分子標的治療薬の有害事象プロファイル―Sorafenib, Regorafenib, Lenvatinibの比較―, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
55.	Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 実臨床におけるLenvatinibの使用経験, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
56.	Tetsu Tomonari, Hironori Tanaka and Tetsuji Takayama : 肝細胞癌に対する肝動脈塞栓術併用Emprint Ablation Systemの治療成績., 第42回日本肝臓学会東部会, Dec. 2018.
57.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : MR Elastographyによる食道胃静脈瘤の治療適応評価., 第26回日本消化器関連学会週間, Nov. 2018.
58.	Jun Okazaki, Toshihito Tanahashi, Hironori Tanaka, Yasuyuki Okada, Yoshihiko Miyamoto, Jinsei Miyoshi, Tatsuya Taniguchi, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : miR-296-5p inhibits apoptosis and enhances invasion through the down-regulated BOK in unresectable pancreatic cancer., 第77回日本癌学会学術集会, Sep. 2018.
59.	Yoshihiko Miyamoto, Hironori Tanaka, Jun Okazaki, Yasuyuki Okada, Tatsuya Taniguchi, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Molecular imaging of colorectal tumor targeting epidermal growth factor receptor (EGFR)., 第77回日本癌学会学術集会, Sep. 2018.
60.	Tadahiko Nakagawa, Toshihito Tanahashi, Yoshihiko Miyamoto, Masanori Takehara, Noriaki Murayama, Hironori Tanaka, Jinsei Miyoshi, Tatsuya Taniguchi, Yoshimi Bando, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌においてCCDC8の発現調節を介して抗癌剤感受性を制御する., 第77回日本癌学会学術総会, Sep. 2018.
61.	Tetsu Tomonari, Yoshihiko Miyamoto, Hironori Tanaka, Takahiro Tanaka and Tetsuji Takayama : 集学的治療奏功例を含む進行肝癌に対する Regorafenib の初期治療成績., 第18回日本肝がん分子標的治療研究会, Jul. 2018.
62.	Tetsu Tomonari, 新居徹, 津保友香, Yoshihiko Miyamoto, Hironori Tanaka, Takahiro Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 集学的治療奏功例を含む進行肝癌に対するRegorafenibの初期治療成績., 第54回日本肝癌研究会, Jun. 2018.
63.	Hironori Tanaka, Tetsu Tomonari and Tetsuji Takayama : 肝細胞癌に対するミリプラチン併用化学放射線療法の検討., 第54回日本肝臓学会総会, Jun. 2018.
64.	Tadahiko Nakagawa, Toshihito Tanahashi, Tetsuo Kimura, Koichi Okamoto, Tatsuya Taniguchi, 村山典聡, Hironori Tanaka, Yoshimi Bando, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌において CCDC8の発現を調節することで薬剤感受性を制御している., 第76回日本癌学会学術総会, Sep. 2017.
65.	村山典聡, Koichi Okamoto, Tadahiko Nakagawa, Tetsuo Kimura, Tatsuya Taniguchi, Hironori Tanaka, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, 藤盛孝博 and Tetsuji Takayama : miR-144-3p/miR-451a はPTEN/p19 を抑制することにより直腸カルチノイド(NET-G1)の浸潤・転移に関与する., 第76回日本癌学会学術総会, Sep. 2017.
66.	Mayu Uyama, Masahiro Sogabe, 平田光里, Tadahiko Nakagawa, Akira Fukuya, Satoshi Teramae, Daisaku Fujimoto, Hironori Tanaka, Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Tetsuji Takayama, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Takahiro Emoto, Masatake Akutagawa, Rumi Katashima and Toshiya Okahisa : 模擬腹水による胸腹水濾過濃縮再静注法の教育体制の構築, 第37回日本アフェレシス学会学術大会, Nov. 2016.
67.	Daiki Tanaka, Naoya Tani, Masanori Takehara, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Tadahiko Nakagawa, Tetsuji Takayama, Masaki Kawano, Takahiro Emoto, Masatake Akutagawa, Yohsuke Kinouchi, Takaaki Shimohata, Takashi Uebanso, Kazuaki Mawatari, Akira Takahashi, Mayu Uyama, Masahiro Sogabe and Toshiya Okahisa : 模擬腹水を用いた胸腹水濾過濃縮装置の評価・教育システムの構築, 第53回日本人工臓器学会大会, Nov. 2015.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

肝細胞癌に対する新規分子標的薬併用化学放射線療法の相乗効果とその機序 (Project/Area Number: 22K15968 )
Role of apoptosis and autophagy in chemoradiotherapy for hepatocellular carcinoma (Project/Area Number: 17K15950 )
Search by Researcher Number (40792388)

Assistant Professor : Tanaka, Hironori

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)